p38 MAPK
The p38 MAPK family consists of highly conserved proline-directed serine-threonine protein kinases that are activated in response to a number many growth factors, cytokines, and chemotactic substances, such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), PDGF, TNF, interleukins, lipopolysaccharide (LPS) and formyl-methionyl-leucyl-phenylalanine (fMLP). It is well known that p38 is involved in inflammation, apoptosis, cardiomyocyte hypertrophy and cell differentiation.
The p38 MAPK family is composed of four proteins: p38α (encoded by the gene Mapk14), p38β (Mapk11), p38γ (Mapk12), and p38δ (Mapk13). Their coding genes have a distinct tissue distribution and they appear differentially expressed, being Mapk14 the most highly expressed. p38 MAPKs are substrates for three MAP2K (MKK6, MKK3, and MKK4). The contribution of each of these MAP2K to p38 MAPKs activation depends on the stimulus and the cell type. The MAP3Ks that lead to p38 MAPKs activation are ASK1, DLK1, TAK1, TAO1, TAO2, TPL2, MLK3, MEKK3, MEKK4, and ZAK1.
p38 MAPK Isoform Specific Products
All Product Categories
-
p38 MAPK Inhibitors
(839)
View all products
-
p38 MAPK Agonists
(6)
View all products
-
p38 MAPK Antagonists
(2)
View all products
-
p38 MAPK Activators
(220)
View all products
-
p38 MAPK Modulators
(21)
View all products
-
p38 MAPK p53 Inhibitors
(2)
View all products
-
p38 MAPK Inducers
(13)
View all products
-
p38 MAPK Degraders
(3)
View all products
-
p38 MAPK Control
(1)
View all products
-
p38 MAPK Ligands
(2)
View all products
-
AKT Serine/Threonine Kinase 1 (AKT1) Proteins
(3)
View all products
-
p38 MAPK Related Products (1199)
Related Products (1199)
-
Recombinant Proteins (3)
-
Antibodies (20)
-
p38 MAPK Isoform Comparison
-
p38-α MAPK-IN-5
0 ImagesCat. No.: HY-147518CAS No.: 1443242-46-3
-
SB-T-101141
0 ImagesCat. No.: HY-106159CAS No.: 186348-05-0SB-T-101141 is a novel taxane. SB-T-101141 effectively induces a noncanonical ferroptosis to overcome Paclitaxel (HY-B0015) resistance of breast cancer. SB-T-101141 facilitates the production of iron and ferrous ions and ROS. SB-T-101141 stably binds to KHSRP to inhibit the iron-dependent expression of CISD1 related to iron homeostasis. SB-T-101141 synergistically enhances the iron-dependent activation of JNK and PERK pathways via KHSRP. SB-T-101141 suppresses breast tumor growth in MCF-7(PR)/MDA-MB-231(PR) or KHSRP knock-down MCF-7 xenograft mice model.
-
Histamine phosphate (Standard)
0 ImagesHistamine phosphate (Standard) is the analytical standard of Histamine phosphate (HY-A0129). This product is intended for research and analytical applications. Histamine phosphate is the agonist for histamine receptor and a vasodilator. Histamine phosphate is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine phosphate affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine phosphate can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma.
-
p38α-IN-14
0 ImagesCat. No.: HY-184936p38α-IN-14 is a selective p38α inhibitor with an IC50 of 65 nM. p38α-IN-14 exhibits only weak inhibitory activity against hERG channels, with an IC50 > 30 μM. p38α-IN-14 can be used in the research of chronic inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriasis and inflammatory bowel disease.
-
BIRB-1017
0 ImagesCat. No.: HY-18861CAS No.: 294848-51-4BIRB-1017 is a potent inhibitor of p38 MAP kinase. BIRB-1017 can be used in inflammation research.
-
R-03201195
0 ImagesCat. No.: HY-18794CAS No.: 249936-55-8R-03201195 is an efficient and selective p38 MAP kinase inhibitor with an IC50 for p38α of 0.7 nM. R-03201195 has inhibitory activity against TNF-α in THP-1 cells and against IL-1β in human whole blood, with IC50 values of 0.25 and 0.57 nM respectively. R-03201195 can be used for inflammatory diseases such as rheumatoid arthritis.
-
BS148
0 ImagesCat. No.: HY-121033CAS No.: 2162116-09-6BS148 is a selective sigma-2 receptor (S2R) agonist with a Ki 20 nM. BS148 shows >80-fold selective for S2R than S1R. BS148 activates the endoplasmic reticulum stress response through the upregulation of protein kinase R-like ER kinase (PERK), activating transcription factor 4 (ATF4) genes, and C/EBP homologous protein (CHOP). BS148 induces apoptosis in melanoma cell. BS148 downregulates genes related to the cholesterol pathway and activates the MAPK signaling pathway. BS148 can be used for the study of melanoma.
-
Glucagon receptor antagonist-8
0 ImagesCat. No.: HY-177156CAS No.: 208182-31-4Glucagon receptor antagonist-8 (Compound 1) is a human glucagon receptor and p38 mitogen-activated protein (MAP) kinase antagonist, with IC50s of 0.27 μM and 0.16 μM, respectively.
-
Suberic acid-13C2
0 ImagesCat. No.: HY-W015300S2CAS No.: 2251773-62-1Synonyms: Octanedioic acid-13C2Suberic acid-13C2 (Octanedioic acid-13C2) is the 13C-labeled Suberic acid (HY-W015300). Suberic acid (Octanedioic acid) is an orally active crystalline dibasic acid. Suberic acid activates the Akt signaling pathway and regulates the expression of molecules related to the TGF-β and MAPK signaling pathways. Suberic acid inhibits skin dryness.
-
Peptide CYP9
0 ImagesCat. No.: HY-P11914CAS No.: 3124554-07-7Peptide CYP9 is a head-to-tail cyclic peptide derived from Antimicrobial peptide YD (HY-P11913). Peptide CYP9 inhibits the activation of the TGF-β/Smad signaling pathway, including the phosphorylation of Smad2/3. Peptide CYP9 inhibits the activation of the MAPK signaling pathway, including the phosphorylation of ERK and p38. Peptide CYP9 inhibits epithelial-mesenchymal transition. Peptide CYP9 inhibits extracellular matrix synthesis. Peptide CYP9 can be used for the research of pulmonary fibrosis.
-
EGFR kinase-IN-8
0 ImagesCat. No.: HY-180922CAS No.: 3081622-35-4EGFR kinase-IN-8 (Compound H8b) is an EGFR inhibitor. EGFR kinase-IN-8 potently inhibits both triple-mutated EGFRL858R/T790M/C797S (IC50 = 3.86 nM) and double-mutated EGFRL858R/T790M (IC50 = 1.23 nM). EGFR kinase-IN-8 suppresses EGFR phosphorylation and downstream AKT, STAT3, and MAPK signaling. EGFR kinase-IN-8 exhibits anticancer activity against non-small cell lung cancer.
-
SMU-R39
0 ImagesCat. No.: HY-175782SMU-R39 is a TLR7 and TLR8 antagonist with IC50 values of 3.22 μM and 0.24 μM, respectively. SMU-R39 binds to recombinant mTLR7 protein (KD = 2.36 μM) and to recombinant hTLR8 protein (KD = 105 nM). SMU-R39 suppresses downstream NF-κB and MAPK signaling, and reduces secretion/transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in PBMCs and THP-1 cells. SMU-R39 demonstrates anti-inflammatory efficacy in Imiquimod (IMQ) (HY-B0180)-induced psoriasis mouse model. SMU-R39 can be used for the study of autoimmune diseases such as psoriasis.
-
Estrogen receptor-IN-2
0 ImagesCat. No.: HY-184982Estrogen receptor-IN-2 is a potent estrogen receptor inhibitor formed by the conjugation of Tam (HY-13757)-NHC and gold (I). Estrogen receptor-IN-2 significantly downregulates estrogen receptor (ER) levels, inhibits ER-mediated downstream signaling pathways, and induces immunogenic cell death (ICD) mediated by damage-associated molecular patterns (DAMPs). Estrogen receptor-IN-2 can overcome drug resistance in MCF-7Y537S mutant cells via the RAMP3/CALCR signaling pathway. It is suitable for research on endocrine-resistant breast cancer.
-
LYRM03
0 ImagesCat. No.: HY-N19847CAS No.: 1820750-36-4LYRM03 is a derivative of Ubenimex (HY-B0134) and a Aminopeptidase N inhibitor. LYRM03 is isolated from Streptomyces HCCB10043. LYRM03 inhibits TLR4, MyD88, NLRP3, ASC, NF-κB and p38 MAPK, stabilizes IκB, and suppresses LPS-induced expression of iNOS and COX-2. LYRM03 reduces the levels of inflammatory cytokines and oxidative stress markers, and alleviates pulmonary edema. LYRM03 exhibits anticancer activity against breast cancer. LYRM03 has anti-inflammatory activity. LYRM03 can be used in the research of acute lung injury and breast cancer.
-
Sertaconazole nitrate (Standard)
0 ImagesSynonyms: FI7056 (Standard)Sertaconazole (nitrate) (Standard) is the analytical standard of Sertaconazole (nitrate). This product is intended for research and analytical applications. Sertaconazole nitrate (FI7056) is a broad-spectrum topical antifungal agent, exhibits anti-inflammatory activity via activation of a p38-COX-2-PGE2 pathway. Sertaconazole nitrate is also a microtubule inhibitor, shows antiproliferative effect, induces apoptosis and autophagy, and can also inhibit the migration of cells.
-
p38 MAPK-IN-10
0 ImagesCat. No.: HY-175433CAS No.: 340041-97-6p38 MAPK-IN-10 (Compound 4) is an orally active and potent p38 MAP kinase inhibitor (IC50=570 nM). p38 MAPK-IN-10 is promising for research of chronic inflammatory diseases such as rheumatoid arthritis and Crohn’s disease.
-
Anticancer agent 319
0 ImagesCat. No.: HY-183316Anticancer agent 319 is an anticancer agent. Anticancer agent 319 inhibits the proliferation of liver cancer cells. Anticancer agent 319 inhibits AKT phosphorylation and blocks the PI3K/AKT signaling axis; meanwhile, it inhibits ERK1/2 phosphorylation and blocks the MAPK/ERK signaling axis. Anticancer agent 319 induces G2/M phase cell cycle arrest, triggers apoptosis, and reduces mitochondrial membrane potential in liver cancer cells. Anticancer agent 319 can be used for the research of hepatocellular carcinoma.
-
Sesamolin (Standard)
0 ImagesSesamolin (Standard) is the analytical standard of Sesamolin. This product is intended for research and analytical applications. Sesamolin, isolated from Sesamum indicum, has antioxidative activity, Sesaminol inhibits lipid peroxidation and shows neuroprotection effect. Sesamolin potently inhibits MAPK cascades by preventing phosphorylation of JNK, p38 MAPKs, and caspase-3 but not ERK-MAPK expression.
